Home > Insider Trading > Filing (0001104659-18-059933)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1382101	Sutro Biopharma Inc	STRO	Pharmaceutical Preparations (2834)	NJ

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
310158	Merck & Co., Inc.	2000 Galloping Hill Road Kenilworth NJ 07033		No	No	Yes	No
942443	Merck Sharp & Dohme Corp.	One Merck Drive Whitehouse Station NJ 08889		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-01	2,056,843	$0.00	2,056,843	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-10-01	666,666	$15.00	2,723,509	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series E Redeemable Convertible Preferred Stock	Disposition	2018-10-01	74,794,315	$0.00	2,056,843	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Each share of Series E redeemable convertible preferred stock (the "Series E Preferred") automatically converted into 0.0275 shares of the Issuer's common stock upon the closing of the Issuer's sale of its common stock in its firm commitment underwritten initial public offering pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended. The Series E Preferred had no expiration date.
These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.